RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
June 06, 2025 16:07 ET Â | Source: Restem MIAMI, June 06, 2025…
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 05, 2025 16:58 ET Â | Source: Boundless Bio, Inc. SAN DIEGO,…
ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
June 05, 2025 16:31 ET  | Source: ImPact Biotech – Previously inoperable…
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Addex Convenes Annual General Meeting 2025
June 03, 2025 01:00 ET Â | Source: Addex Therapeutics Geneva, Switzerland, June…
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
June 02, 2025 04:00 ET Â | Source: Aravax MELBOURNE, Australia and OXFORD,…
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor,…
